A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”

Wei Seong Toh; Reza Yarani; Samir El Andaloussi; Byong Seung Cho; Chulhee Choi; Randolph Corteling; Antonin De Fougerolles; Mario Gimona; Josephine Herz; Maroun Khoury; Paul D. Robbins; Douglas Williams; Daniel J. Weiss; Eva Rohde; Bernd Giebel; Sai Kiang Lim

doi:10.1016/j.jcyt.2023.02.009

A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”

Wei Seong Toh, Reza Yarani, Samir El Andaloussi, Byong Seung Cho, Chulhee Choi, Randolph Corteling, Antonin De Fougerolles, Mario Gimona, Josephine Herz, Maroun Khoury, Paul D. Robbins, Douglas Williams, Daniel J. Weiss, Eva Rohde, Bernd Giebel^*, Sai Kiang Lim^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The International Society for Cell & Gene Therapy Scientific Signature Series event “Therapeutic Advances With Native and Engineered Human EVs” took place as part of the International Society for Cell & Gene Therapy 2022 Annual Meeting, held from May 4 to 7, 2022, in San Francisco, California, USA. This was the first signature series event on extracellular vesicles (EVs) and a timely reflection of the growing interest in EVs, including both native and engineered human EVs, for therapeutic applications. The event successfully gathered academic and industrial key opinion leaders to discuss the current state of the art in developing and understanding native and engineered EVs and applying our knowledge toward advancing EV therapeutics. Latest advancements in understanding the mechanisms by which native and engineered EVs exert their therapeutic effects against different diseases in animal models were presented, with some diseases such as psoriasis and osteoarthritis already reaching clinical testing of EVs. The discussion also covered various aspects relevant to advancing the clinical translation of EV therapies, including EV preparation, manufacturing, consistency, site(s) of action, route(s) of administration, and luminal cargo delivery of RNA and other compounds.

Original language	English
Pages (from-to)	810-814
Number of pages	5
Journal	Cytotherapy
Volume	25
Issue number	8
DOIs	https://doi.org/10.1016/j.jcyt.2023.02.009
State	Published - Aug 2023
Externally published	Yes

Bibliographical note

Funding Information:
WST and SKL are supported by the Agency for Science, Technology, and Research under its Health and Biomedical Sciences Industry Alignment Fund Pre-positioning (award no. H19H6a0026 ). RY is supported by Lundbeck foundation grant R303-2018-3148 .

Funding Information:
WST and SKL are supported by the Agency for Science, Technology, and Research under its Health and Biomedical Sciences Industry Alignment Fund Pre-positioning (award no. H19H6a0026). RY is supported by Lundbeck foundation grant R303-2018-3148. Conception and design of the study: BG and SKL. Acquisition of data: WST, RY, SEIA, BSC, CC, RC, ADF, MG, JH, MK, PDR, DW, DJW and ER. Analysis and interpretation of data: WST, RY, SEIA, BSC, CC, RC, ADF, MG, JH, MK, PDR, DW, DJW and ER. Drafting or revising the manuscript: WST, RY, BG and SKL. All authors have approved the final article.

Publisher Copyright:
© 2023 International Society for Cell & Gene Therapy

Keywords

clinical trials
exosomes
extracellular vesicles
mesenchymal stromal cells
therapeutic
translation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jcyt.2023.02.009

Cite this

Toh, W. S., Yarani, R., El Andaloussi, S., Cho, B. S., Choi, C., Corteling, R., De Fougerolles, A., Gimona, M., Herz, J., Khoury, M., Robbins, P. D., Williams, D., Weiss, D. J., Rohde, E., Giebel, B., & Lim, S. K. (2023). A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”. Cytotherapy, 25(8), 810-814. https://doi.org/10.1016/j.jcyt.2023.02.009

@article{abe22819288841e0aae0a9ab1b9a4de4,

title = "A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”",

abstract = "The International Society for Cell & Gene Therapy Scientific Signature Series event “Therapeutic Advances With Native and Engineered Human EVs” took place as part of the International Society for Cell & Gene Therapy 2022 Annual Meeting, held from May 4 to 7, 2022, in San Francisco, California, USA. This was the first signature series event on extracellular vesicles (EVs) and a timely reflection of the growing interest in EVs, including both native and engineered human EVs, for therapeutic applications. The event successfully gathered academic and industrial key opinion leaders to discuss the current state of the art in developing and understanding native and engineered EVs and applying our knowledge toward advancing EV therapeutics. Latest advancements in understanding the mechanisms by which native and engineered EVs exert their therapeutic effects against different diseases in animal models were presented, with some diseases such as psoriasis and osteoarthritis already reaching clinical testing of EVs. The discussion also covered various aspects relevant to advancing the clinical translation of EV therapies, including EV preparation, manufacturing, consistency, site(s) of action, route(s) of administration, and luminal cargo delivery of RNA and other compounds.",

keywords = "clinical trials, exosomes, extracellular vesicles, mesenchymal stromal cells, therapeutic, translation",

author = "Toh, {Wei Seong} and Reza Yarani and {El Andaloussi}, Samir and Cho, {Byong Seung} and Chulhee Choi and Randolph Corteling and {De Fougerolles}, Antonin and Mario Gimona and Josephine Herz and Maroun Khoury and Robbins, {Paul D.} and Douglas Williams and Weiss, {Daniel J.} and Eva Rohde and Bernd Giebel and Lim, {Sai Kiang}",

note = "Funding Information: WST and SKL are supported by the Agency for Science, Technology, and Research under its Health and Biomedical Sciences Industry Alignment Fund Pre-positioning (award no. H19H6a0026 ). RY is supported by Lundbeck foundation grant R303-2018-3148 . Funding Information: WST and SKL are supported by the Agency for Science, Technology, and Research under its Health and Biomedical Sciences Industry Alignment Fund Pre-positioning (award no. H19H6a0026). RY is supported by Lundbeck foundation grant R303-2018-3148. Conception and design of the study: BG and SKL. Acquisition of data: WST, RY, SEIA, BSC, CC, RC, ADF, MG, JH, MK, PDR, DW, DJW and ER. Analysis and interpretation of data: WST, RY, SEIA, BSC, CC, RC, ADF, MG, JH, MK, PDR, DW, DJW and ER. Drafting or revising the manuscript: WST, RY, BG and SKL. All authors have approved the final article. Publisher Copyright: {\textcopyright} 2023 International Society for Cell & Gene Therapy",

year = "2023",

month = aug,

doi = "10.1016/j.jcyt.2023.02.009",

language = "English",

volume = "25",

pages = "810--814",

journal = "Cytotherapy",

issn = "1465-3249",

publisher = "Elsevier Inc.",

number = "8",

}

Toh, WS, Yarani, R, El Andaloussi, S, Cho, BS, Choi, C, Corteling, R, De Fougerolles, A, Gimona, M, Herz, J, Khoury, M, Robbins, PD, Williams, D, Weiss, DJ, Rohde, E, Giebel, B & Lim, SK 2023, 'A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”', Cytotherapy, vol. 25, no. 8, pp. 810-814. https://doi.org/10.1016/j.jcyt.2023.02.009

TY - JOUR

T1 - A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”

AU - Toh, Wei Seong

AU - Yarani, Reza

AU - El Andaloussi, Samir

AU - Cho, Byong Seung

AU - Choi, Chulhee

AU - Corteling, Randolph

AU - De Fougerolles, Antonin

AU - Gimona, Mario

AU - Herz, Josephine

AU - Khoury, Maroun

AU - Robbins, Paul D.

AU - Williams, Douglas

AU - Weiss, Daniel J.

AU - Rohde, Eva

AU - Giebel, Bernd

AU - Lim, Sai Kiang

N1 - Funding Information: WST and SKL are supported by the Agency for Science, Technology, and Research under its Health and Biomedical Sciences Industry Alignment Fund Pre-positioning (award no. H19H6a0026 ). RY is supported by Lundbeck foundation grant R303-2018-3148 . Funding Information: WST and SKL are supported by the Agency for Science, Technology, and Research under its Health and Biomedical Sciences Industry Alignment Fund Pre-positioning (award no. H19H6a0026). RY is supported by Lundbeck foundation grant R303-2018-3148. Conception and design of the study: BG and SKL. Acquisition of data: WST, RY, SEIA, BSC, CC, RC, ADF, MG, JH, MK, PDR, DW, DJW and ER. Analysis and interpretation of data: WST, RY, SEIA, BSC, CC, RC, ADF, MG, JH, MK, PDR, DW, DJW and ER. Drafting or revising the manuscript: WST, RY, BG and SKL. All authors have approved the final article. Publisher Copyright: © 2023 International Society for Cell & Gene Therapy

PY - 2023/8

Y1 - 2023/8

N2 - The International Society for Cell & Gene Therapy Scientific Signature Series event “Therapeutic Advances With Native and Engineered Human EVs” took place as part of the International Society for Cell & Gene Therapy 2022 Annual Meeting, held from May 4 to 7, 2022, in San Francisco, California, USA. This was the first signature series event on extracellular vesicles (EVs) and a timely reflection of the growing interest in EVs, including both native and engineered human EVs, for therapeutic applications. The event successfully gathered academic and industrial key opinion leaders to discuss the current state of the art in developing and understanding native and engineered EVs and applying our knowledge toward advancing EV therapeutics. Latest advancements in understanding the mechanisms by which native and engineered EVs exert their therapeutic effects against different diseases in animal models were presented, with some diseases such as psoriasis and osteoarthritis already reaching clinical testing of EVs. The discussion also covered various aspects relevant to advancing the clinical translation of EV therapies, including EV preparation, manufacturing, consistency, site(s) of action, route(s) of administration, and luminal cargo delivery of RNA and other compounds.

AB - The International Society for Cell & Gene Therapy Scientific Signature Series event “Therapeutic Advances With Native and Engineered Human EVs” took place as part of the International Society for Cell & Gene Therapy 2022 Annual Meeting, held from May 4 to 7, 2022, in San Francisco, California, USA. This was the first signature series event on extracellular vesicles (EVs) and a timely reflection of the growing interest in EVs, including both native and engineered human EVs, for therapeutic applications. The event successfully gathered academic and industrial key opinion leaders to discuss the current state of the art in developing and understanding native and engineered EVs and applying our knowledge toward advancing EV therapeutics. Latest advancements in understanding the mechanisms by which native and engineered EVs exert their therapeutic effects against different diseases in animal models were presented, with some diseases such as psoriasis and osteoarthritis already reaching clinical testing of EVs. The discussion also covered various aspects relevant to advancing the clinical translation of EV therapies, including EV preparation, manufacturing, consistency, site(s) of action, route(s) of administration, and luminal cargo delivery of RNA and other compounds.

KW - clinical trials

KW - exosomes

KW - extracellular vesicles

KW - mesenchymal stromal cells

KW - therapeutic

KW - translation

UR - http://www.scopus.com/inward/record.url?scp=85150016214&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2023.02.009

DO - 10.1016/j.jcyt.2023.02.009

M3 - Article

AN - SCOPUS:85150016214

SN - 1465-3249

VL - 25

SP - 810

EP - 814

JO - Cytotherapy

JF - Cytotherapy

IS - 8

ER -

A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this